|
|
Vaccine Detail
|
6F-Tn-MUC1-alpha-GalCer Nanoliposomal Vaccine |
| Vaccine Information |
- Vaccine Name: 6F-Tn-MUC1-alpha-GalCer Nanoliposomal Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: PDTRP, Tn at T3 (Dong et al., 2022)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic two-component self-adjuvanting nanoliposomal antitumor vaccine comprising a fluorinated Tn-MUC1 glycopeptide based on the PDTRP motif — the most immunogenic domain of MUC1 — bearing 6-fluoro-Tn O-glycan at threonine with PEG spacer at C-terminus, covalently conjugated to amino-modified α-GalCer (KRN 7000) via EDCI coupling, formulated into nanoliposomes (~105 nm, PDI: 0.113, zeta potential −24.5 mV) with DSPC and cholesterol. C-6 fluorine substitution on GalNAc enhances epitope immunogenicity over native Tn antigen; α-GalCer acts as built-in adjuvant binding CD1d on APCs, activating iNKT cells and driving IFN-γ and IL-4 production. Subcutaneous immunization of Balb/c mice (days 0, 14, 28; 5 μg Tn antigen/dose) elicited the highest anti-Tn-MUC1-specific IgG titer of 22,400, 2.3-fold over non-fluorinated nanoliposomal V1 (9,600) and ~9-fold over its soluble, non-nanoliposomal fluorinated conjugate M2, demonstrating the combined benefit of fluorine substitution and nanoliposomal delivery. Non-conjugated controls V3 (F-Tn-MUC1/α-GalCer mixture) and V4 (F-Tn-MUC1 alone) failed to activate the immune system, confirming covalent conjugation is essential. V2 yielded highest absolute levels of all isotypes (IgG1, IgG2a, IgG2b) with predominantly high IgG2a but lowest IgG2a/IgG1 ratio, indicating mixed Th1/Th2 response contrasting with Th1-skewed V1; all groups produced low IgM. FACS and CDC assays confirmed strongest MCF-7 binding and cytotoxic killing, with no significant weight loss observed (Dong et al., 2022).
|
| Host Response |
|
|
| References |
Dong et al., 2022: Dong P, Cheng S, Wang Y, Gao H, Zhang Y, Zhu T, Yu P, Meng X. A self-adjuvanting anti-tumor nanoliposomal vaccine based on fluorine-substituted MUC1 glycopeptide. Chemical communications (Cambridge, England). 2022; 58(62); 8642-8645. [PubMed: 35820186].
|
|
